Titlis Pharma (Private) Limited
Private pharmaceutical manufacturer · Lahore · Pakistan
Lahore pharmaceutical manufacturer established in 2014 with GMP/ISO-oriented production, contract manufacturing and export activity.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Private pharmaceutical manufacturer
- Address
- 528-A, Sundar Industrial Estate, Raiwind Road, Lahore, Pakistan
- Website
- titlispharma.com ↗
- Phone
- +92 42 35297692-5; +92 349 4563570
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 88%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Azipos | Azithromycin | 250 mg | Capsule | 10'S | 078812 | PKR 508.66 | PKR 50.87/capsule | Near median |
| Azipos | Azithromycin | 500 mg | Tablet | 6's | 102618 | PKR 441.57 | PKR 73.60/tablet | 13% below median |
| Azipos | Azithromycin | 200 mg/5 mL | Suspension | 15ml | 115425 | PKR 340.79 | PKR 22.72/mL | Near median |
| Carbatit | Carbamazepine | 200 mg | Tablet | 30's | 119316 | PKR 340.78 | PKR 11.36/tablet | 5% above median |
| Carbatit | Carbamazepine | 200 mg | Tablet | 50's | 119316 | PKR 540.84 | PKR 10.82/tablet | Near median |
| Ciprolis | Ciprofloxacin | 500 mg | Tablet | 10's | 078821 | PKR 437.79 | PKR 43.78/tablet | Near median |
| Ciprolis | Ciprofloxacin | 250 mg | Tablet | 10's | 085179 | PKR 264.70 | PKR 26.47/tablet | Near median |
| Ciprolis | Ciprofloxacin | 125 mg/5 mL | Dry suspension | 60ml | 116676 | PKR 222.36 | PKR 3.71/mL | Near median |
| Ciprolis | Ciprofloxacin | 250 mg/5 mL | Dry suspension | 60ml | 116677 | PKR 330.46 | PKR 5.51/mL | 9% above median |
| Conazit | Fluconazole | 150 mg | Capsule | 4's | 078813 | PKR 1,013.31 | PKR 253.33/capsule | Near median |
| Conazit | Fluconazole | 150 mg | Capsule | 1's | 078813 | PKR 281.00 | PKR 281.00/capsule | 7% above median |
| Dapatit | Dapagliflozin | 5 mg | Tablet | 14's | 115200 | PKR 1,461.19 | PKR 104.37/tablet | 60% above median |
| Dapatit | Dapagliflozin | 5 mg | Tablet | 10's | 115200 | PKR 1,043.04 | PKR 104.30/tablet | 60% above median |
| Dapatit | Dapagliflozin | 10 mg | Tablet | 14's | 115201 | PKR 1,543.42 | PKR 110.24/tablet | 62% above median |
| Dapatit | Dapagliflozin | 10 mg | Tablet | 10's | 115201 | PKR 1,101.77 | PKR 110.18/tablet | 62% above median |
| GerEpo | Erythropoietin | 2000 IU | Injection | 1's Vial | 084786 | PKR 2,090.69 | PKR 2,090.69/vial/unit | Near median |
| GerEpo | Erythropoietin | 3000 IU | Injection | 1's Vial | 084787 | PKR 3,158.18 | PKR 3,158.18/vial/unit | No comparator |
| GerEpo | Erythropoietin | 4000 IU | Injection | 1's Vial | 084788 | PKR 3,983.85 | PKR 3,983.85/vial/unit | Near median |
| GerEpo | Erythropoietin | 5000 IU | Injection | 1's Vial | 084789 | PKR 5,149.56 | PKR 5,149.56/vial/unit | No comparator |
| GerEpo | Erythropoietin | 2000 IU | Prefilled syringe injection | 1's PFS | 084790 | PKR 2,090.69 | PKR 2,090.69/syringe | 20% above median |
| GerEpo | Erythropoietin | 3000 IU | Prefilled syringe injection | 1's PFS | 084791 | PKR 3,158.18 | PKR 3,158.18/syringe | No comparator |
| GerEpo | Erythropoietin | 4000 IU | Prefilled syringe injection | 5's | 084792 | PKR 18,222.28 | PKR 3,644.46/syringe | Near median |
| GerEpo | Erythropoietin | 4000 IU | Prefilled syringe injection | 1's PFS | 084792 | PKR 3,983.85 | PKR 3,983.85/syringe | 16% above median |
| Ibulis Liquid | Ibuprofen | 200 mg/5 mL | Suspension | 90ml | 078814 | PKR 125.34 | PKR 1.39/mL | 12% above median |
| Ibulis Liquid | Ibuprofen | 100 mg/5 mL | Suspension | 90 ml | 078815 | PKR 87.52 | PKR 0.97/mL | Near median |
| Ibulis Liquid | Ibuprofen | 100 mg/5 mL | Suspension | 120 ml | 078815 | PKR 135.50 | PKR 1.13/mL | 19% above median |
| Irobest | Iron polymaltose complex | 50 mg/5 mL | Syrup | 60ml | 078816 | PKR 151.36 | PKR 2.52/mL | 9% above median |
| Irobest | Iron polymaltose complex | 50 mg/5 mL | Syrup | 120ml | 078816 | PKR 273.96 | PKR 2.28/mL | Near median |
| Irobest-F | Iron polymaltose complex + Folic acid | 100 mg elemental iron + 0.35 mg folic acid | Chewable tablet | 10's | 085840 | PKR 168.89 | PKR 16.89/tablet | 24% above median |
| Irobest-F | Elemental Iron | 100 mg | Chewable tablet | 20's | 085840 | PKR 311.59 | PKR 15.58/tablet | Near median |
| Irobest-F | Iron polymaltose complex + Folic acid | 100 mg + 0.35 mg | Chewable tablet | 30's | 085840 | PKR 457.86 | PKR 15.26/tablet | 12% above median |
| Irotit | Polysaccharide iron complex | 100 mg/5 mL | Syrup | 120ml | 110606 | PKR 176.58 | PKR 1.47/mL | 28% below median |
| Irotit | Polysaccharide iron complex | 150 mg | Capsule | 30's | 110607 | PKR 466.18 | PKR 15.54/capsule | 35% below median |
| Levolis | Levofloxacin | 500 mg | Tablet | 10's | 078820 | PKR 829.79 | PKR 82.98/tablet | Near median |
| Levolis | Levofloxacin | 250 mg | Tablet | 10's | 085178 | PKR 498.67 | PKR 49.87/tablet | Near median |
| Lisformin | Metformin | 500 mg | Tablet | 50's | 078823 | PKR 133.70 | PKR 2.67/tablet | Near median |
| Lopilis 200 | Lopinavir + Ritonavir | 200 mg + 50 mg | Tablet | 120's | 106020 | PKR 11,525.21 | PKR 96.04/tablet | Near median |
| LVT | Levetiracetam | 250 mg | Tablet | 30's | 102616 | PKR 1,441.19 | PKR 48.04/tablet | 13% below median |
| LVT | Levetiracetam | 250 mg | Tablet | 10's | 102616 | PKR 480.40 | PKR 48.04/tablet | 13% below median |
| LVT | Levetiracetam | 500 mg | Tablet | 30's | 102617 | PKR 2,389.77 | PKR 79.66/tablet | 17% below median |
| LVT | Levetiracetam | 500 mg | Tablet | 10's | 102617 | PKR 796.59 | PKR 79.66/tablet | 17% below median |
| Metrolis | Metronidazole | 200 mg/5 mL | Oral suspension | 90ml | 078818 | PKR 99.02 | PKR 1.10/mL | Near median |
| Metrolis | Metronidazole | 200 mg/5 mL | Oral suspension | 120ml | 078818 | PKR 135.57 | PKR 1.13/mL | Near median |
| Metrolis | Metronidazole | 200 mg/5 mL | Oral suspension | 60 ml | 078818 | PKR 69.17 | PKR 1.15/mL | Near median |
| Moxilis | Moxifloxacin | 400 mg | Tablet | 5's | 078824 | PKR 947.48 | PKR 189.50/tablet | Near median |
| Omsta | Omeprazole | 20 mg | Capsule | 14's | 078871 | PKR 297.40 | PKR 21.24/capsule | 8% above median |
| Omsta | Omeprazole | 40 mg | Capsule | 14's | 097530 | PKR 401.43 | PKR 28.67/capsule | 17% below median |
| ORS | Sodium chloride | 2.60 g | Sachet | 20's | 121493 | PKR 521.15 | PKR 26.06/sachet | 9% above median |
| Oselvir | Oseltamivir | 75 mg | Capsule | 10's | 106021 | PKR 1,125.51 | PKR 112.55/capsule | 7% below median |
| Respiklar | Clarithromycin | 250 mg | Tablet | 10's | 093552 | PKR 465.97 | PKR 46.60/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.